Identification of Genes Down-regulated During Lung Cancer Progression: a CDNA Array Study

Overview

Journal J Exp Clin Cancer Res

Publisher Biomed Central

Specialty Oncology

Date 2008 Sep 17

PMID 18793406

Citations 19

Authors

Mara Campioni

Vincenzo Ambrogi

Eugenio Pompeo

Gennaro Citro

Mauro Castelli

Enrico P Spugnini

Antonio Gatti

Pierluigi Cardelli

Laura Lorenzon

Alfonso Baldi

Tommaso C Mineo

Affiliations

Soon will be listed here.

Abstract

Background: Lung cancer remains a major health challenge in the world. Survival for patients with stage I disease ranges between 40-70%. This suggests that a significant proportion of patients with stage I NSCLC may actually be under-staged.

Methods: In order to identify genes relevant for lung cancer development, we carried out cDNA array experiments employing 64 consecutive patients (58 men and 6 women) with a median age of 58 years and stage 1 or stage 2 non-small-cell lung cancer (NSCLC).

Results: Basic cDNA array data identified 14 genes as differentially regulated in the two groups. Quantitative RT-PCR analysis confirmed an effective different transcriptional regulation of 8 out of 14 genes analyzed. The products of these genes belong to different functional protein types, such as extra-cellular matrix proteins and proteases (Decorin and MMP11), genes involved in DNA repair (XRCC1), regulator of angiogenesis (VEGF), cell cycle regulators (Cyclin D1) and tumor-suppressor genes (Semaphorin 3B, WNT-5A and retinoblastoma-related Rb2/p130). Some previously described differences in expression patterns were confirmed by our array data. In addition, we identified and validated for the first time the reduced expression level of some genes during lung cancer progression.

Conclusion: Comparative hybridization by means of cDNA arrays assisted in identifying a series of novel progression-associated changes in gene expression, confirming, at the same time, a number of previously described results.

Citing Articles

The SEMA3F-NRP1/NRP2 axis is a key factor in the acquisition of invasive traits in in situ breast ductal carcinoma.

Moragas N, Fernandez-Nogueira P, Recalde-Percaz L, Inman J, Lopez-Plana A, Bergholtz H Breast Cancer Res. 2024; 26(1):122.

PMID: 39138514 PMC: 11320849. DOI: 10.1186/s13058-024-01871-0.

Cancer-associated fibroblasts in early-stage lung adenocarcinoma correlate with tumor aggressiveness.

Vasiukov G, Zou Y, Senosain M, Rahman J, Antic S, Young K Sci Rep. 2023; 13(1):17604.

PMID: 37848457 PMC: 10582049. DOI: 10.1038/s41598-023-43296-3.

Simulation Study of cDNA Dataset to Investigate Possible Association of Differentially Expressed Genes of Human THP1-Monocytic Cells in Cancer Progression Affected by Bacterial Shiga Toxins.

Muhammad S, Guo J, Nguyen T, Wu X, Bai B, Yang X Front Microbiol. 2018; 9:380.

PMID: 29593668 PMC: 5859033. DOI: 10.3389/fmicb.2018.00380.

The role of the semaphorins in cancer.

Neufeld G, Mumblat Y, Smolkin T, Toledano S, Nir-Zvi I, Ziv K Cell Adh Migr. 2016; 10(6):652-674.

PMID: 27533782 PMC: 5160032. DOI: 10.1080/19336918.2016.1197478.

DCN deficiency promotes renal cell carcinoma growth and metastasis through downregulation of P21 and E-cadherin.

Xu Y, Xia Q, Rao Q, Shi S, Shi Q, Ma H Tumour Biol. 2015; 37(4):5171-83.

PMID: 26547587 DOI: 10.1007/s13277-015-4160-1.

References

Baldi A, Battista T, De Luca A, Santini D, Rossiello L, Baldi F . Identification of genes down-regulated during melanoma progression: a cDNA array study. Exp Dermatol. 2003; 12(2):213-8. DOI: 10.1034/j.1600-0625.2003.00026.x. View

Mineo T, Ambrogi V, Baldi A, Rabitti C, Bollero P, Vincenzi B . Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol. 2004; 57(6):591-7. PMC: 1770311. DOI: 10.1136/jcp.2003.013508. View

Shintani K, Matsumine A, Kusuzaki K, Morikawa J, Matsubara T, Wakabayashi T . Decorin suppresses lung metastases of murine osteosarcoma. Oncol Rep. 2008; 19(6):1533-9. View

Esposito V, Baldi A, Liuzzi G, Tonini G, Vincenzi B, Persichetti P . Analysis of Fas (Apo-1/CD95) expression in non-small cell lung cancer. Anticancer Res. 2004; 23(6C):4901-5. View

Weaver D, Crawford E, Warner K, Elkhairi F, Khuder S, Willey J . ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol Cancer. 2005; 4(1):18. PMC: 1156938. DOI: 10.1186/1476-4598-4-18. View

DAmico T, Aloia T, Moore M, Herndon 2nd J, Brooks K, Lau C . Molecular biologic substaging of stage I lung cancer according to gender and histology. Ann Thorac Surg. 2000; 69(3):882-6. DOI: 10.1016/s0003-4975(99)01522-2. View

Nimri C, Stoner G, Lubet R, You M . Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas. Clin Cancer Res. 2002; 8(4):1127-38. View

Caputi M, Esposito V, Baldi A, De Luca A, Dean C, Signoriello G . p21waf1/cip1mda-6 expression in non-small-cell lung cancer: relationship to survival. Am J Respir Cell Mol Biol. 1998; 18(2):213-7. DOI: 10.1165/ajrcmb.18.2.2937m. View

Karameris A, Panagou P, Tsilalis T, Bouros D . Association of expression of metalloproteinases and their inhibitors with the metastatic potential of squamous-cell lung carcinomas. A molecular and immunohistochemical study. Am J Respir Crit Care Med. 1997; 156(6):1930-6. DOI: 10.1164/ajrccm.156.6.9612046. View

10.

Castro-Rivera E, Ran S, Thorpe P, Minna J . Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. Proc Natl Acad Sci U S A. 2004; 101(31):11432-7. PMC: 509218. DOI: 10.1073/pnas.0403969101. View

11.

Macchiarini P, Fontanini G, Hardin M, SQUARTINI F, Angeletti C . Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet. 1992; 340(8812):145-6. DOI: 10.1016/0140-6736(92)93217-b. View

12.

Paggi M, Baldi A, Bonetto F, Giordano A . Retinoblastoma protein family in cell cycle and cancer: a review. J Cell Biochem. 1996; 62(3):418-30. DOI: 10.1002/(SICI)1097-4644(199609)62:3%3C418::AID-JCB12%3E3.0.CO;2-E. View

13.

Spugnini E, Campioni M, DAvino A, Caruso G, Citro G, Baldi A . Cell-cycle molecules in mesothelioma: an overview. J Exp Clin Cancer Res. 2008; 26(4):443-9. View

14.

Esposito V, Campioni M, De Luca A, Spugnini E, Baldi F, Cassandro R . Analysis of HtrA1 serine protease expression in human lung cancer. Anticancer Res. 2006; 26(5A):3455-9. View

15.

Esposito V, Baldi A, De Luca A, Tonini G, Vincenzi B, Santini D . Cell cycle related proteins as prognostic parameters in radically resected non-small cell lung cancer. J Clin Pathol. 2005; 58(7):734-9. PMC: 1770708. DOI: 10.1136/jcp.2004.023531. View

16.

Offersen B, Pfeiffer P, Hamilton-Dutoit S, Overgaard J . Patterns of angiogenesis in nonsmall-cell lung carcinoma. Cancer. 2001; 91(8):1500-9. View

17.

Pukrop T, Binder C . The complex pathways of Wnt 5a in cancer progression. J Mol Med (Berl). 2007; 86(3):259-66. DOI: 10.1007/s00109-007-0266-2. View

18.

Baldi A, Esposito V, De Luca A, Fu Y, Meoli I, GIORDANO G . Differential expression of Rb2/p130 and p107 in normal human tissues and in primary lung cancer. Clin Cancer Res. 1998; 3(10):1691-7. View

19.

Yano T, Tanikawa S, Fujie T, Masutani M, Horie T . Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer. Eur J Cancer. 2000; 36(5):601-9. DOI: 10.1016/s0959-8049(99)00327-5. View

20.

Liu D, Huang C, Kameyama K, Hayashi E, Yamauchi A, Kobayashi S . E-cadherin expression associated with differentiation and prognosis in patients with non-small cell lung cancer. Ann Thorac Surg. 2001; 71(3):949-54; discussion 954-5. DOI: 10.1016/s0003-4975(00)02545-5. View